BIIB News

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 28 strange trades.

Over the past 3 months, 6 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

According to Benzinga Pro, during Q1, Biogen (NASDAQ:BIIB) earned $218.50 million, a 1165.85% increase from the preceding quarter. Biogen's sales decreased to $2.53 billion, a 7.39% change since Q4.

Biogen (NASDAQ:BIIB) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an earnings per share (EPS) of $4.38.